share_log

Recent 8.2% Pullback Isn't Enough to Hurt Long-term Innovative Medical ManagementLtd (SZSE:002173) Shareholders, They're Still up 26% Over 1 Year

Recent 8.2% Pullback Isn't Enough to Hurt Long-term Innovative Medical ManagementLtd (SZSE:002173) Shareholders, They're Still up 26% Over 1 Year

最近8.2%的回调不足以伤害长期创新医疗管理有限公司(SZSE:002173)的股东,他们在1年内仍上涨了26%
Simply Wall St ·  2023/12/08 17:05

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Innovative Medical Management Co.,Ltd. (SZSE:002173) share price is up 26% in the last 1 year, clearly besting the market decline of around 11% (not including dividends). That's a solid performance by our standards! Longer term, the stock is up 24% in three years.

投资股票的最简单方法是购买交易所交易基金。但是,您可以通过选择高于平均水平的股票来显著提高回报。例如,创新医疗管理公司。,Ltd.(SZSE:002173)的股价在过去1年中上涨了26%,显然超过了约11%(不包括股息)的市场跌幅。按照我们的标准,这是一项不错的表现!从长远来看,该股在三年内上涨了24%。

Since the long term performance has been good but there's been a recent pullback of 8.2%, let's check if the fundamentals match the share price.

由于长期表现良好,但最近出现了8.2%的回调,让我们来看看基本面是否与股价相符。

View our latest analysis for Innovative Medical ManagementLtd

查看我们对创新医疗管理有限公司的最新分析

Given that Innovative Medical ManagementLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

鉴于Innovative Medical Medical ManagementLtd在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。无利可图公司的股东通常预计收入将强劲增长。那是因为可以很容易地推断出快速的收入增长来预测利润,而利润通常规模相当大。

Innovative Medical ManagementLtd grew its revenue by 8.1% last year. That's not a very high growth rate considering it doesn't make profits. In keeping with the revenue growth, the share price gained 26% in that time. While not a huge gain tht seems pretty reasonable. Given the market doesn't seem too excited about the stock, a closer look at the financial data could pay off, if you can find indications of a stronger growth trend in the future.

去年,创新医疗管理有限公司的收入增长了8.1%。考虑到它无法获利,这并不是一个很高的增长率。为了与收入增长保持一致,股价在此期间上涨了26%。虽然收益不大,但这似乎很合理。鉴于市场似乎对该股并不太兴奋,如果你能发现未来增长趋势更强劲的迹象,仔细观察财务数据可能会得到回报。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(随着时间的推移)如下图所示(点击查看确切数字)。

earnings-and-revenue-growth
SZSE:002173 Earnings and Revenue Growth December 8th 2023
深圳证券交易所:002173 收益和收入增长 2023年12月8日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在这张免费的交互式图片中看到其资产负债表如何随着时间的推移而增强(或减弱)。

A Different Perspective

不同的视角

We're pleased to report that Innovative Medical ManagementLtd shareholders have received a total shareholder return of 26% over one year. That gain is better than the annual TSR over five years, which is 3%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Innovative Medical ManagementLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Innovative Medical ManagementLtd .

我们很高兴地向大家报告,Innovative Medical Medical ManagementLtd的股东在一年内获得了26%的股东总回报率。该增幅优于五年内的年度股东总回报率,后者为3%。因此,最近公司周围的情绪似乎一直乐观。持乐观观点的人可能会将最近股东总回报率的改善视为业务本身随着时间的推移而变得越来越好。从长远来看,追踪股价表现总是很有意思的。但是,为了更好地了解创新医疗管理有限公司,我们需要考虑许多其他因素。为此,你应该注意我们在Innovative Medical ManagementLtd发现的1个警告信号。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你想看看另一家公司——一家财务状况可能优异的公司——那么千万不要错过这份已经证明自己可以增加收益的公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发